Tiamenidine


Tiamenidine is an imidazoline compound that shares many of the pharmacological properties of clonidine. It is a centrally-acting α2 adrenergic receptor agonist. It also acts as an α1-adrenergic receptor agonist to a far lesser extent. In hypertensive volunteers, like clonidine, it significantly increased sinus node recovery time and lowered cardiac output. It was marketed by Sanofi-Aventis under the brand name Sundralen for the management of essential hypertension.

Synthesis

Reaction of thiourea 1 with methyl iodide gives the corresponding S-methyl analogue, followed by heating with ethylenediamine, completes the synthesis of tiamenidine.